Načítá se...
Key questions about the checkpoint blockade-are microRNAs an answer?
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early phase 3 clinical trials. The therapeutic indicat...
Uloženo v:
| Vydáno v: | Cancer Biol Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Chinese Anti-Cancer Association
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994554/ https://ncbi.nlm.nih.gov/pubmed/29951335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2018.0006 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|